Literature DB >> 15449043

Immunohistochemical characterisation of the monoclonal antibody BLCA-38 for the detection of prostate cancer.

P J Russell1, K T Ow, P N Tam, J Juarez, E A Kingsley, C F Qu, Y Li, P J Cozzi, R Martiniello-Wilks.   

Abstract

BACKGROUND: Monoclonal antibodies (MAbs) can be used to detect, image and treat cancers. This study aimed to characterise the binding of BLCA-38 MAbs to human prostate cancer cell lines, human prostate cancer biopsy samples and normal tissues to enable future targeted studies.
METHODS: BLCA-38 antigen expression on cancer lines was determined by flow cytometry; that on patient specimens from normal tissues and cancers was tested by immunohistochemistry using fresh frozen tissues or paraffin-embedded tissues that had undergone antigen retrieval.
RESULTS: Cell surface BLCA-38 antigen expression was seen on DU-145, PC-3, PC-3 M and PC-3 M-MM2 prostate cancer lines, but LNCaP, MDA PCa 2a or MDA PCa 2b lines were negative. Other human lines, including 8/12 bladder cancer and A431 vulval epidermoid cells, but not breast cancer lines, expressed BLCA-38 antigen. Staining occurred in glandular epithelial cells in the majority of frozen, and paraffin-embedded prostate cancer tissues and was occasionally seen in prostatic intraepithelial neoplasia (PIN). No staining was observed in normal cadaver tissues or in benign areas from various other cancer tissues.
CONCLUSIONS: The BLCA-38 antibody binds to the majority of human prostate cancers but not to normal cells, and has potential for targeting novel therapies in patients with this disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15449043     DOI: 10.1007/s00262-004-0527-7

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  10 in total

1.  Stable Upconversion Nanohybrid Particles for Specific Prostate Cancer Cell Immunodetection.

Authors:  Yu Shi; Bingyang Shi; Arun V Everest Dass; Yiqing Lu; Nima Sayyadi; Liisa Kautto; Robert D Willows; Roger Chung; James Piper; Helena Nevalainen; Bradley Walsh; Dayong Jin; Nicolle H Packer
Journal:  Sci Rep       Date:  2016-11-22       Impact factor: 4.379

2.  Development of a reliable assay to measure glypican-1 in plasma and serum reveals circulating glypican-1 as a novel prostate cancer biomarker.

Authors:  Rachel A Levin; Maria E Lund; Quach Truong; Angela Wu; Neal D Shore; Daniel R Saltzstein; Raoul S Concepcion; Thomas A Paivanas; Arletta van Breda; Jennifer Beebe-Dimmer; Julie J Ruterbusch; Sandra Wissmueller; Douglas H Campbell; Bradley J Walsh
Journal:  Oncotarget       Date:  2018-04-27

3.  Detection of glypican-1 (GPC-1) expression in urine cell sediments in prostate cancer.

Authors:  Douglas H Campbell; Maria E Lund; Aline L Nocon; Paul J Cozzi; Mark Frydenberg; Paul De Souza; Belinda Schiller; Jennifer L Beebe-Dimmer; Julie J Ruterbusch; Bradley J Walsh
Journal:  PLoS One       Date:  2018-04-19       Impact factor: 3.240

4.  Targeted beta therapy of prostate cancer with 177Lu-labelled Miltuximab® antibody against glypican-1 (GPC-1).

Authors:  Mei-Chun Yeh; Brian W C Tse; Nicholas L Fletcher; Zachary H Houston; Maria Lund; Marianna Volpert; Chelsea Stewart; Kamil A Sokolowski; Varinder Jeet; Kristofer J Thurecht; Douglas H Campbell; Bradley J Walsh; Colleen C Nelson; Pamela J Russell
Journal:  EJNMMI Res       Date:  2020-05-07       Impact factor: 3.138

5.  Near-Infrared Molecular Imaging of Glioblastoma by Miltuximab®-IRDye800CW as a Potential Tool for Fluorescence-Guided Surgery.

Authors:  Dmitry M Polikarpov; Douglas H Campbell; Lucinda S McRobb; Jiehua Wu; Maria E Lund; Yanling Lu; Sergey M Deyev; Andrew S Davidson; Bradley J Walsh; Andrei V Zvyagin; David A Gillatt
Journal:  Cancers (Basel)       Date:  2020-04-16       Impact factor: 6.639

6.  Functionalized Upconversion Nanoparticles for Targeted Labelling of Bladder Cancer Cells.

Authors:  Dmitry Polikarpov; Liuen Liang; Andrew Care; Anwar Sunna; Douglas Campbell; Bradley Walsh; Irina Balalaeva; Andrei Zvyagin; David Gillatt; Evgenii Guryev
Journal:  Biomolecules       Date:  2019-12-03

7.  A bispecific T cell engager targeting Glypican-1 redirects T cell cytolytic activity to kill prostate cancer cells.

Authors:  Maria E Lund; Christopher B Howard; Kristofer J Thurecht; Douglas H Campbell; Stephen M Mahler; Bradley J Walsh
Journal:  BMC Cancer       Date:  2020-12-10       Impact factor: 4.430

8.  Safety and tolerability of Miltuximab® - a first in human study in patients with advanced solid cancers.

Authors:  Dhanusha Sabanathan; Douglas H Campbell; Vicki M Velonas; Sandra Wissmueller; Hubert Mazure; Marko Trifunovic; Pirooz Poursoltan; Kevin Ho Shon; Tiffany R Mackay; Maria E Lund; Yanling Lu; Paul J Roach; Dale L Bailey; Bradley J Walsh; David Gillatt; Howard Gurney
Journal:  Asia Ocean J Nucl Med Biol       Date:  2021

9.  Glypican-1 as a Biomarker for Prostate Cancer: Isolation and Characterization.

Authors:  Quach Truong; Irene O Justiniano; Aline L Nocon; Julie T Soon; Sandra Wissmueller; Douglas H Campbell; Bradley J Walsh
Journal:  J Cancer       Date:  2016-05-21       Impact factor: 4.207

Review 10.  Bee Venom Components as Therapeutic Tools against Prostate Cancer.

Authors:  Jasmin Katrin Badawi
Journal:  Toxins (Basel)       Date:  2021-05-07       Impact factor: 4.546

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.